1	An integrated multi-omics analysis of sleep-disordered breathing traits across multiple
2	blood cell types
3	
4	Nuzulul Kurniansyah ¹ , Danielle A Wallace ¹ , Ying Zhang ¹ , Bing Yu ¹² , Brian Cade, ^{1,7,20} Heming
5	Wang ^{1,7,20} Heather M. Ochs-Balcom ⁴ , Alexander P Reiner ^{5,6} , Alberto R Ramos ¹⁰ , Joshua D
6	Smith ¹¹ , Jianwen Cai ¹⁴ , Martha Daviglus ¹⁵ , Phyllis C Zee ¹⁶ , Robert Kaplan ^{21,5} , Charles
7	Kooperberg ⁵ , Stephen S Rich ¹⁸ , Jerome I Rotter ⁹ , Sina A. Gharib ¹⁹ , Susan Redline, ^{1,20} Tamar
8	Sofer ^{1,2,*}
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	 ¹Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA ²Departments of Medicine and of Biostatistics, Harvard University, Boston, MA, USA ⁴Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, NY, USA ⁵Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA ⁶Department of Epidemiology, University of Washington, Seattle, Washington, USA ⁷The Broad Institute of MIT and Harvard, Cambridge, MA, USA ⁸Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA ⁹The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA USA ¹⁰Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA ¹¹Northwest Genomic Center, University of Washington, Seattle, WA, USA ¹²Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, TX 77030, USA ¹³Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA ¹⁴Department of Biostatistics, University of North Carolina, at Chapel Hill, NC, USA ¹⁵Institute for Minority Health Research, University fol Illinois at Chicago, Chicago, IL, USA ¹⁶Division of Cardiology and Neurology, Duke University Medical Center, Durham, NC, 27710, USA ¹⁸Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA ¹⁹Department of Sleep Medicine, Harvard Medical School, Boston, MA, USA ²⁰Division of Sleep

- 43 tsofer@bwh.harvard.edu
- 44 Suite 225C
- 45 221 Longwood Ave
- 46 Boston, MA, 02115
- 47
- 48
- 49

50 ABSTRACT

51 **Background:** Sleep Disordered Breathing (SDB) is characterized by repeated breathing

52 reductions or cessations during sleep, often accompanied by oxyhemoglobin desaturation. How

53 SDB affects the molecular environment is still poorly understood.

54 **Methods:** We studied the association of three SDB measures: the Apnea Hypopnea Index

55 (AHI), average and minimum oxyhemoglobin saturation during sleep (AvgO2 and MinO2) with

56 gene expression measured using RNA-seq in peripheral blood mononuclear cells (PBMCs),

57 monocytes, and T-cells, in ~500 individuals from the Multi-Ethnic Study of Atherosclerosis

58 (MESA). We developed genetic instrumental variables (IVs) for the associated transcripts as

59 polygenic risk scores (tPRS), then generalized and validated the tPRS in the Women's Health

60 Initiative (WHI). Next, we constructed the tPRS and studied their association with SDB

61 measures (to identify potential reverse causal associations) and with serum metabolites (to

62 identify downstream effects) in ~12,000 and ~4,000 participants, respectively, from the Hispanic

63 Community Health Study/Study of Latinos (HCHS/SOL). Finally, we estimated the association of

64 these SDB measures with transcript IV-associated metabolites in HCHS/SOL, to verify complete

65 association pathways linking SDB, gene expression, and metabolites.

66 **Results:** Across the three leukocyte cell types, 96 gene transcripts were associated with at

67 least one SDB exposure (False Discovery Rate (FDR) p-value <0.1). Across cell populations,

- 68 estimated log-fold expression changes were similar between AHI and MinO2 (Spearman
- 69 correlations>0.90), and less similar between AvgO2 and the other exposures. Eight and four

- associations had FDR p-value<0.05 when the analysis was not adjusted and adjusted to BMI,
- 71 respectively. Associations include known genes that respond to (*PDGFC*) and regulate
- 72 response to (AJUBA) hypoxia. We identified a complete "chain" linking AvgO2, P2RX4, and
- 73 butyrylcarnitine (C4), suggesting that increased expression of the purinergic receptor *P2RX4*
- 74 may improve average oxyhemoglobin saturation and decrease butyrylcarnitine (C4) levels.
- 75 **Conclusions:** Our results support a mechanistic role for purinergic signaling and hypoxic
- signaling, among others, in SDB. These findings show differential gene expression by blood cell
- 77 type in relation to SDB traits and link *P2XR4* expression to influencing AvgO2 and
- 58 butyrylcarnitine (C4) levels. Overall, we employed novel methods for integrating multi-omic data
- 79 to evaluate biological mechanisms underlying multiple SDB traits.
- 80
- 81 Keywords
- 82 Average oxyhemoglobin saturation, Apnea hypopnea index, Minimum oxyhemoglobin satura-
- tion, RNA-seq, Peripheral blood mononuclear cells, Monocyte, T-cell, Instrumental variables,
- 84 Sleep disordered breathing.

85 BACKGROUND

86 Sleep-disordered breathing (SDB) is a common disorder, affecting an estimated 24% of male 87 and 9% of female adults in the U.S. (1). SDB is characterized by episodic periods of breathing 88 cessations and reductions during sleep, often accompanied by oxyhemoglobin desaturation 89 (2,3), and is associated with cardiometabolic, vascular, and cognitive outcomes (4-7). SDB is 90 also strongly associated with inflammation (8.9). While obesity is a strong risk factor for SDB, 91 SDB is also heritable independent of body mass index (BMI) (10,11). The underlying molecular 92 processes by which SDB affects health outcomes are still being studied (12), with interest in un-93 derstanding SDB-related hypoxia during sleep on cardiometabolic and vascular measures in 94 humans and in animal models (13-15). 95 96 In investigating the molecular changes caused by SDB, previous studies showed changes in 97 distributions and activation of white blood cells (16-18) and inflammatory cytokines (19) in 98 individuals with obstructive sleep apnea (OSA). Other studies reported changes in gene 99 expression in white blood cells following treatment using continuous positive airway pressure 100 (CPAP), or following CPAP withdrawal (20–23), supporting a causal role between SDB-related 101 physiological stressors (such as hypoxia) and immune cell gene expression. Some studies, 102 including those from our group, also reported cross-sectional transcriptomic association with 103 SDB measures from observational studies (23,24). However, these studies focused on a single 104 cell population, and it is unknown whether and how transcriptional effects of SDB differ among 105 circulating leukocyte subpopulations. Likewise, it is yet unknown how SDB-alterations in gene 106 expression translate to metabolic changes. A few previous studies reported associations of 107 blood metabolites with SDB phenotypes, independently of transcriptomics. For example, one 108 study reported change in serum metabolite levels, evaluated on an untargeted platform that 109 surveyed a few hundred metabolites, after multi-level sleep surgery (25). Most other studies 110 considered specific, targeted metabolite changes in sleep disorders (see reviews in (26)).

111

Large, untargeted, omics surveys are now becoming available in cohort studies, providing an opportunity to study the association of SDB with well-defined, genetically-regulated molecular measures. We deploy a systems biology approach integrating genomic, transcriptomic, and metabolomic data to identify potential pathways in tissue-specific mechanisms driving SDBrelated morbidity.

117

118 Utilizing data from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Hispanic 119 Community Health Study/Study of Latinos (HCHS/SOL), we examined multi-omics data to 120 investigate signaling mechanisms underlying SDB traits. First, we used transcriptomics data 121 measured in peripheral blood mononuclear cells (PBMCs), T-cells and monocytes, assayed by 122 the Trans-Omics for Precision Medicine (TOPMed) program, to perform transcriptome-wide 123 association study of SDB-related phenotypes (measured via overnight polysomnography) in 124 MESA. We compared the results across different peripheral blood cell populations. With these 125 data, we constructed transcript polygenic risk scores (tPRS) predicting transcript expression 126 using genetic data. Next, we built these tPRS in the Women's Health Initiative (WHI) and tested 127 them for association and generalization with their transcripts in whole blood. We calculated the 128 tPRS that generalized in HCHS/SOL. Finally, we applied these tPRS to SDB traits and 129 metabolites in HCHS/SOL to investigate how SDB phenotypes potentially propagate via 130 transcription to metabolic changes in serum, and on the other direction, to assess potential 131 reverse association by which transcript expression causes changes in SDB phenotypes. 132 133 **METHODS**

134

135 **Overall study design and purpose**

136 The overall purpose of the study was to investigate the multi-omics signaling mechanisms 137 underlying SDB traits to better understand possible drivers of morbidity in SDB. The study 138 design and purpose of each analysis component is illustrated in **Figure 1**. Briefly, panel A 139 demonstrates the set of associations investigated: SDB phenotypes lead to transcriptional 140 changes which in turn lead to metabolic changes; panel B describes the analysis steps taken to 141 study the potential chain of associations, and the goal of each of these steps. To optimize the 142 available sample size and leverage the fact that transcription is, to some extent, genetically 143 determined, we utilized two separate cohorts to identify the biological components associated 144 sleep exposure to metabolomic changes. Figure 2 further illustrates potential causal 145 relationships underlying a set of measures, and the assumptions that we used to interrogate 146 some of them. Thus, we first performed transcriptome-wide association studies for SDB 147 phenotypes in MESA. For each transcript associated with a SDB trait (FDR p-value <0.1), we 148 used genetic data to construct a transcript Polygenic Risk Score (tPRS) to serve as a predictor 149 of the transcript. Next, to reduce false positive associations in subsequent analyses, we 150 constructed these tPRS in the WHI and tested their association and generalization with their 151 transcripts in whole blood. We proceeded with tPRS results that generalized (p-value <0.05), 152 and constructed and tested them latter for association with SDB phenotypes in HCHS/SOL. If a 153 tPRS was associated with the SDB phenotype in HCHS/SOL, it was interpreted as evidence of 154 reverse association, i.e., the transcript may contribute to SDB. We then calculated the 155 association of the tPRS with metabolites in HCHS/SOL. Lastly, we used another analytic step to 156 support the existence of an association chain linking a sleep exposure, a transcript, and a 157 metabolite: we required evidence of association between the sleep exposure and the metabolite 158 in HCHS/SOL (i.e. any of the potential pathways in column A of Figure 2). If the tPRS was 159 associated with the sleep exposure in HCHS/SOL, it lent support to association chains where 160 the transcript affects both SDB and metabolite levels.





Flow charts illustrating the methodology and purpose of the analysis. The chart portrays the three SDB phenotypes evaluated in the analysis, the three blood tissues with transcript expression measurement, and demonstrates each step of the analysis with associated goals, cohorts, and reasons why step was performed. Penal A: conceptual linking between SDB measures, transcript expression, and metabolites. Panel B: analytic steps supporting the study of the conceptual links. PBMC tPRS analysis sample sizes in MESA correspond to data from two visits (some individuals were used twice, appropriately accounted for by mixed models).

162

164

Figure 2: Potential association "chains" of SDB traits, transcript expression, and metabolites, addressed in this study.



The figure illustrates association chains, or pathways, potentially linking an SDB trait, a transcript, and a metabolite. Here we assume that an association between a sleep trait and a transcript was detected in MESA and is assumed "known" for follow-up analysis in WHI in HCHS/SOL. Column A demonstrates potential forms of causal associations between the sleep trait and the transcript, including (A.4) the settings where an association exists due to a common cause, e.g. BMI. Our metabolomics analysis may only detect transcript-metabolite associations, i.e. any sleep-metabolite link is via transcript levels. Column B demonstrate a potential conclusion from an association between a tPRS, validated in WHI and used as an instrumental variable (IV) of a transcript, and a sleep trait: if an association is detected, it provides evidence that changes in transcript levels are upstream (a cause of) changes in sleep trait levels. Column C demonstrates potential conclusions from analyses linking tPRS and a sleep trait to a metabolite. A tPRS is used to link a transcript to a metabolite, and an association, if exists, is likely causal. A sleep-metabolite association should exist if the sleeptranscript and tPRS-transcript associations hold, and therefore observing such an association validates the existence of any of A pathways. Further association between the tPRS and the sleep trait narrows down the potential association chains to A.2 or A.3.

165

166 **Participating studies**

- 167 As described in Figure 1, our analysis included three studies: MESA, WHI, and HCHS/SOL
- 168 each contributing to different analytical steps. The three studies are described in the
- 169 Supplementary Information. In brief, MESA, our primary study used for discovery of SDB-

transcript associations, is a longitudinal cohort study (27). The 1st and 5th MESA exams took 170 171 place between 2000-2002, and 2010-2012, respectively, and whole blood was drawn from 172 participants in both exams. For about 1,000 participants, blood was used later for RNA 173 extraction in at least one of the exams. In addition, a sleep study ancillary to MESA occurred 174 shortly after MESA exam 5 during 2010-2013. Sleep study participants underwent single night 175 in-home polysomnography, as previously described (28). The number of individuals with each 176 type of data and at each time point (exam 1 and exam 5) varies. Figure S1 in the 177 Supplementary Information visualizes the data flow and overlaps across the various measures 178 used in this study: whole-genome genotyping, RNA-seq, and sleep. All MESA participants 179 provided written informed consent, and the study was approved by the Institutional Review 180 Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at 181 Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, 182 Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins 183 University. 184

The WHI was here used to identify tPRS that could be confidently used as IVs for their traits. It is a prospective national health study focused on identifying optimal strategies for preventing chronic diseases that are the major causes of death and disability in postmenopausal women (29). 11,071 WHI participants have whole-genome sequencing data via TOPMed, and 1,274 of these participants have RNA-seq measured in venous blood via TOPMed. All WHI participants provided informed consent and the study was approved by the IRB of the Fred Hutchinson Cancer Research Center.

192

193 The HCHS/SOL was used to establish association chains that include an SDB trait, a transcript,

and a metabolite. It is a longitudinal cohort study of U.S. Hispanics/Latinos (30,31). The

195 HCHS/SOL baseline exam occurred on 2008-2011, where 16,415 participants were enrolled.

196 HCHS/SOL individuals who consented further participated in an in-home sleep study, using a 197 validated type 3 home sleep apnea test recording airflow (via nasal pressure), oximetry, 198 position, and snoring. Genetic data were measured and imputed to the TOPMed freeze 5b 199 reference panel, as previously described, for individuals who consented at baseline (32,33). 200 Metabolomic data were also measured for n=~4,000 individuals selected at random out of those 201 with genetic data (34). Figure S2 in the Supplementary Information provides the data flow in 202 HCHS/SOL, focusing on individuals with genetic data and wide consent for genetic data 203 sharing. The HCHS/SOL was approved by the institutional review boards (IRBs) at each field 204 center, where all participants gave written informed consent, and by the Non-Biomedical IRB at 205 the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All 206 IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel 207 Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva 208 University. Bronx, NY: IRB at Office for the Protection of Research Subjects (OPRS), University 209 of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, 210 FL; Institutional Review Board of San Diego State University, San Diego, CA.

211

212 **RNA sequencing**

213 For both MESA and WHI, RNA-seq was performed via the Trans-Omics in Precision Medicine 214 (TOPMed) program. In MESA, RNA-seq was generated from three blood cell types: peripheral 215 blood mononuclear cells (PBMCs; ~n=1,200 measured in blood from visits 1 and 5), and 216 specific components: T-cells, and monocytes (referred to as T-cell and Mono, for both: n=416), 217 measured in blood from visit 5. Samples were sequenced at the Broad Institute and at the North 218 West Genomics Center (NWGC). Both centers used harmonized protocols. RNA samples 219 quality was assessed using RNA Integrity Number (RIN, Agilent Bioanalyzer) prior to shipment 220 to sequencing centers. QC was re-performed at sequencing centers by RIN analysis at the 221 NWGC and by RNA Quality Score analysis (RQS, Caliper) at the Broad Institute. A minimum of

- 222 250ng RNA sample was required as input for library construction, performed using the Illumina
- 223 TruSeq[™] Stranded mRNA Sample Preparation Kit. RNA was sequenced as 2x101bp paired-
- 224 end reads on the Illumina HiSeq 4000 according to the manufacturer's protocols. Target
- 225 coverage was of ≥40M reads. Comprehensive information about the RNA-seq pipeline used for
- 226 TOPMed can be found in <u>https://github.com/broadinstitute/gtex-</u>
- 227 pipeline/blob/master/TOPMed_RNAseq_pipeline.md under MESA RNA-seq pilot commit
- 228 725a2bc. Here we used gene-level expected counts quantified using RSEM v1.3.0 (35). RNA
- sequencing for WHI (whole blood) was performed at the Broad Institute using the unified
- 230 TOPMed protocols. More information about RNA-seq in WHI is provided in the Supplemental
- 231 Information.
- 232

233 Metabolomics data in HCHS/SOL

234 Metabolomics profiling using fasting blood samples was conducted at Metabolon (Durham, NC)

with Discovery HD4 platform in 2017. Serum metabolites were quantified with untargeted, liquid

- chromatography-mass spectrometry (LC-MS)-based quantification protocol (36,37). The plat-
- form captured a total of 1,136 metabolites, including 782 known and 354 unknown (unidentified)

238 metabolites. Detailed methodologic information is provided elsewhere (34).

239

240 Phenotypic measures of sleep-disordered breathing (SDB)

241 We used three SDB measures, as measured by overnight sleep studies in MESA and

242 HCHS/SOL (methods above): (1) the Apnea-Hypopnea Index (AHI), defined in MESA as the

- 243 number of apneas (breathing cessation) and hypopneas (at least 30% reduction of breath
- volume, accompanied by 3% or higher reduction of oxyhemoglobin saturation) per hour of

sleep, and in HCHS/SOL, due to differences in the recording montage compared to MESA, as

the number of apnea or hypopnea events with 3% desaturation per hour of sleep; (2) minimum

247 oxyhemoglobin saturation during sleep (MinO2), and (3) average oxyhemoglobin saturation
248 during sleep (AvgO2).

249

Testing the association between SDB and blood cell-specific transcriptome-wide gene expression

252 We used the Olivia R package (38) to perform association analyses of gene expression in 253 PBMCs, monocytes, and T-cells with each of the three SDB measures, separately and in a joint 254 analysis in MESA. SDB phenotypes were treated as the exposures. We followed the 255 recommended Olivia pipeline. Briefly, we performed median normalization, and then filtered 256 lowly expressed gene transcripts defined by removing transcripts with proportion of zero higher 257 than 0.5, median value lower than 1, maximum expression range value lower than 5, and 258 maximum expression value lower than 10. Transcript counts were log transformed after counts 259 of zero were replaced with half the minimum of the observed transcript count in the sample. The 260 analyses were adjusted for age, sex, study center, race/ethnic group, and batch variables: 261 plates, shipment batch, and study site. Because BMI is a strong risk factor for SDB and is 262 assumed to be part of the causal chain, we conducted additional analyses adjusting for BMI 263 (BMIadi). We computed empirical p-values to account for the highly skewed distribution of SDB 264 phenotypes, which may lead to false negative associations if ignored. Finally, we accounted for 265 multiple testing by applying False-Discovery Rate (FDR) correction to each of the association 266 analyses using the Benjamini-Hochberg (BH) procedure (39). We carried forward transcript 267 associations with FDR p-value<0.1 for additional analyses and visualized their association with 268 SDB phenotypes via a hierarchically-clustered heatmap.

269

270 Transcript polygenic risk scores (tPRS) construction and validation

271 To develop tPRS, we first performed a genome-wide association study (GWAS) for each SDB-

associated transcript using the MESA TOPMed WGS dataset; each GWAS adjusted for age

273 (years), sex, study site, self-reported race/ethnic background, and 11 principal components, and 274 analyses were restricted to genetic variants with a minor allele frequency of at least 0.05 (due to 275 low sample size). For each GWAS, we used the fully-adjusted two-stage procedure for rank-276 normalizing residuals in association analyses (40) to identify genetic variants associated with 277 transcript expression. For PBMCs, we used transcript measures from the two MESA visits with 278 RNA-seg data to increase power. To do this, we removed related individuals, and used a 279 random effect model that accounted for individuals. Summary statistics from the GWAS for each 280 transcript were used to develop PRS weights for the corresponding transcript. Next, we 281 constructed tPRS in MESA. We applied clump and threshold implemented in PRSice2 v2.3.1.e 282 (41) using clumping parameters $R^2=0.1$, distance of 250Kb, and three p-value thresholds (5x10⁻ 283 ⁸,10⁻⁷, 10⁻⁶). For each transcript, we constructed the three tPRS in WHI. A tPRS with the 284 smallest p-value in association with the transcript in WHI, and also having p-285 value<0.05/3=0.017, was selected and considered validated. We also computed FDR-adjusted 286 p-values based on all constructed tPRS (3 candidate tPRS per gene across all genes). To test 287 the association of the tPRS with transcript in WHI, we used logistic mixed models, executed with 288 the GENESIS R package (42) version 2.16.1. Each tPRS served as the exposure, and 289 transcripts served as the outcome, here too using the two-stage procedure for rank-290 normalization (40). Relatedness was modeled via a sparse kinship matrix among TOPMed WHI 291 individuals. We selected transcripts with p-value <0.017 for follow-up analysis. 292

We validated that our approach to construct tPRS is robust. We compared a few polygenic prediction models developed using bulk RNAseq in monocytes. First, the prediction model developed using prediXcan based on the MESA dataset (43,44), with weights provided in the predictDB database (http://www.predictdb.org/). Second, our approach above using genomewide SNPs (including trans-eQTLs), and third, a similar clump and threshold approach as above limited to cis-eQTLs defined as SNPs within 1Mbp of the start and end position of the transcript

- (the definition used by prediXcan). We focused on monocytes for this comparison becauseprediXcan models were only published based on monocytes.
- 301
- 302

303 Using tPRS to identify reverse association between gene expression and SDB traits

304 We constructed generalized tPRS in HCHS/SOL. We used HCHS/SOL genotypes imputed to 305 the TOPMed freeze5b reference panel. Prior to tPRS construction, we filtered SNPs with impu-306 tation guality <0.8, minor allele frequency <5%, missingness rate >0.01. As illustrated in column 307 B of **Figure 2**, We identified potential reverse causation, where gene expression alters SDB, by 308 using the tPRS constructed in HCHS/SOL as instrumental variables (IVs) and testing their asso-309 ciation with their respective SDB phenotypes in HCHS/SOL. We used logistic mixed models, ex-310 ecuted with the GENESIS R package (42) version 2.16.1. Each tPRS served as the exposure, 311 and the relevant SDB phenotype served as the outcome. To account for skewness of the SDB phenotypes, we used the two-stage procedure for rank-normalization (40). Relatedness was 312 313 modeled via a sparse kinship matrix, household sharing, and block unit sharing among 314 HCHS/SOL individuals. Association analyses were adjusted for age, sex, study site, His-315 panic/Latino background, the first 5 PCs of the genetic data, and log of the sampling weights 316 used to sample HCHS/SOL individuals into the study. Because the tPRS represent a genetic 317 proxy for gene expression, if a tPRS was found to be associated with a SDB phenotype (p-318 value<0.05), it provided evidence that the transcript contributed to the SDB phenotype, rather 319 than vice versa. However, as illustrated in diagrams A.2 and A.3 in **Figure 2** for sleep-transcript 320 association, bidirectional associations are also plausible.

321

322 Associations between tPRS and metabolites

323 Treating tPRS as genetic IVs for gene expression, we estimated associations between tPRS
 324 and all identified (named) metabolites with < 25% missing values in HCHS/SOL. We used

325 robust survey models implemented in the R survey package version 4.0 (45), accounting for 326 HCHS/SOL study design (probability sampling and clustering) and providing associations 327 generalizable to the HCHS/SOL target population. For each metabolite, we first imputed 328 observations with missing values of that metabolite with its minimum value observed in the 329 sample, under the assumption that missing values are due to concentrations being below the 330 detection limit, and then rank-normalized it across the sample. We used the same covariates as 331 before: age, sex, study site, Hispanic background, and the first 5 PCs of the genetic data. 332 Furthermore, we adjusted for BMI depending on the original association of the SDB phenotype 333 and the transcript (BMI unadjusted or BMI adjusted). For each transcript, we corrected 334 metabolite associations to account for FDR using the Benjamini-Hochberg (BH) procedure (39). 335 Associations were considered significant if the FDR p-value was <0.05. 336 337 Association analyses of SDB traits with selected metabolites to verify a complete associ-338 ation chain 339 To further validate a complete association "chain" as detailed in **Figure 2**, we performed 340 association analyses between the SDB phenotypes and metabolites identified in the tPRS 341 analysis. Associations between SDB phenotypes and metabolites used a survey sampling 342 approach to account for HCHS/SOL sampling design and obtained estimates generalizable to 343 the HCHS/SOL target population. Thus, we used the survey R package (46) with each individual 344 weighted by their sampling weights, and clustering accounted for when computing robust 345 standard errors. Analyses were adjusted for age, sex, study site, Hispanic/Latino background. 346 and BMI depending on the original detected SDB-transcript association (BMI unadjusted or BMI 347 adjusted). If an SDB phenotype was associated with the metabolite (p-value<0.05), we 348 interpreted this as validation of a SDB association with this metabolite via the transcript-level 349 chain.

351 **RESULTS**

352 Sample characteristics

353 Characteristics of the MESA population that participated in the TOPMed omics study, the sleep

- 354 study, and the smaller T-cells and monocytes analyses are provided in **Table S1**; characteristics
- of the HCHS/SOL participants with genetic and metabolite data are provided in **Table S2**.
- 356 MESA individuals are a multi-ethnic sample, 69 years old on average during MESA exam 5, and
- 357 52% female. HCHS/SOL individuals are from diverse Hispanic/Latino backgrounds with a mean
- age of 46 years during the baseline exam, and 59% female. SDB phenotypes were more severe
- in MESA, with average AHI=18.6, MinO2=83, and AvgO2=94.1, in contrast to HCHS/SOL with
- 360 average AHI=6.4, MinO2=87.1, and AvgO2=96.4, consistent with the older age of the MESA
- 361 sample. Characteristics of the WHI participants with RNA-seq data used to validate the tran-
- 362 script PRS are provided in **Table S3**. WHI individuals are from a multi-race and ethnic sample
- 363 and are 80 years old on average at the Long-Life Study exam when RNA was extracted, and
- are all females.
- 365

366 SDB phenotypes for oxyhemoglobin saturation and AHI are linked to tissue-specific

367 changes in the transcriptome

In MESA, we identified 96 and 24 differentially expressed transcripts (Table S4, S5 and Table
S6, S7) with FDR p-value < 0.1 in unadjusted and adjusted BMI analyses, respectively, in the
different cell types. Table 1 reports the top differentially expressed transcripts (FDR p-value
<0.05). Three transcripts, *AJUBA* (Ajuba LIM Protein), *ZNF665* (Zinc Finger Protein 665), and *TMC3-AS1* (TMC3 Antisense RNA 1, a long non-coding RNA), are significantly associated with
AvgO2 and AHI in both analyses, in the direction of reduced expression with worse SDB
measures (higher AHI, lower AvgO2).

376

r I	U	nadjusted for	BMI		
0		Duralina			
Gene	Adj LFC	P-value	ғық р-	SDB Trait	Cell Type
			value		
AJUBA	0.104	2.59E-06	0.050	AvgO2	PBMCs
PDGFC	-0.016	2.59E-06	0.050	MinO2	PBMCs
SIAE	-0.011	1.26E-06	0.020	MinO2	Monocytes
EMP1	-0.030	6.91E-06	0.050	-	
LHFPL2	-0.014	9.42E-06	0.050	-	
ZNF665	-0.011	2.74E-07	0.003	AHI	T-cells
FAM106A	-0.032	7.69E-06	0.047	_	
TMC3-AS1	-0.022	2.74E-07	0.003	_	
	I	Adjusted for E	3 <i>MI</i>		1
Gene	Adj LFC	P-value	FDR- p-	SDB Trait	Cell Type
			value		
AJUBA	0.116	2.59E-07	0.005	AvgO2	PBMCs
ZNF665	-0.012	5.49E-07	0.010	AHI	T-cells
DUX4L27	-0.029	6.59E-06	0.043		
TMC3-AS1	-0.021	7.14E-06	0.043	_	
The table provides (n=4 transcripts) for expression per 1 u	results from analy or BMI. "Adj LFC" is Init increase in SDE	ses of unadju the covariate exposure. P	sted (n=8 t e-adjusted -value is th	ranscripts) ar log2-fold chan ne raw p-value	nd adjusted nge in gene e, and FDR p-

For AvgO2 and MinO2, negative Adj LFC indicates increased expression with worse SDB symptoms. For AHI, positive Adj LFC indicates increased expression with worse SDB

--

symptoms.

378 To visualize gene expression and compare across SDB traits and cell types. Spearman 379 correlation of log-fold change in expression of all SDB-associated transcripts (n=96 transcripts 380 FDR p<0.1) was illustrated with a heatmap for BMI unadjusted (Figure S3) and BMI adjusted 381 (Figure S4) analyses, clustered using hierarchical clustering based on the correlation between 382 the log-fold estimates. These results illustrate concordant and discordant patterns of differential 383 gene expression by cell type (PBMCs, monocytes, and T-cells) and SDB trait (AvgO2, MinO2, 384 and AHI). There are a few striking differences in gene expression, particularly the increased 385 expression of FAM106A, DNAJA3, BCDIN3D-AS1, TGFBRAP1, BEND5, TTC24, TMC3-AS1, 386 LINC00235, SEC14L2, ARHGEF9, TSHZ1, and LA16c-312E8.4 in T-cells compared to 387 monocytes and PBMCs. To further investigate the overall patterns in gene expression in relation 388 to tissue type and SDB traits, a heatmap of the Spearman correlation of the log-fold expression 389 estimates of SDB phenotypes was plotted Figure 3. Within cell types, the SDB traits AHI and 390 MinO2 had the highest correlation for gene expression (Spearman R^2 between 0.91 to 0.97). 391 whereas AvgO2 had lower correlations with AHI and MinO2, especially in monocytes. In 392 addition, a heatmap of estimated log-fold gene expression change (FDR p-value < 0.1) with 393 SDB phenotypes across tissues adjusted for BMI is shown in Figure S5. The correlations 394 between the SDB effect estimates for gene expression across cell types are different, and 395 generally higher, from the phenotypic correlations between the SDB phenotypes, which are at 396 the range of 0.53 to 0.73 Spearman R^2 (**Figure S6**). When computing correlations over all 397 genes, estimated associations between AvgO2 with gene expression had almost no correlation 398 with the other phenotypes (Figure S7). The same patterns (although slightly attenuated) are 399 observed in BMI adjusted analyses (Figure S8).

Figure 3: Spearman correlations between estimated log-fold changes in gene expres-



sion across SDB phenotypes and blood cell types without BMI adjustment in MESA

Heatmap illustrating the Spearman correlations of log-fold change of transcript expression by tissue type (monocytes, T-cells, PBMCs) and SDB phenotype (AvgO2, MinO2, AHI) in MESA. Correlations were computed over genes with FDR p<0.1. Color legend portrays Spearman R^2 (no/weak correlation = light yellow; complete/strong correlation = green). Estimated AHI effect sizes were flipped prior to computation of correlations so that they match the direction of MinO2 and AvgO2.

401

402

403 Construction and validation of transcript PRS

- 404 We constructed tPRS for gene expression in monocytes using a few methods, focusing on
- 405 transcripts that were associated with SDB exposures in our analysis. The performance of

406 constructed tPRS was evaluated against whole-blood gene expression levels in n=1.269 WHI 407 participants. Figure S9 visualizes the results, demonstrating that tPRS constructed using the 408 clump and threshold for genome-wide SNPs, including trans-eQTLs and tPRS focusing on cis-409 eQTLs have similar results, and the same generalization rate as that of the prediXcan-based 410 tPRS. However, prediXcan tPRS had opposite direction of association with one of the 411 transcripts in WHI, and, both cis-eQTLs based tPRS (prediXcan and clump and threshold) were 412 not available for some transcripts due to lack of transcript-associated SNPs near the coding 413 region. Thus, we moved forward with the genome-wide approach. Of the 96 tPRS (BMI 414 unadjusted analysis) and 24 tPRS (BMI-adjusted analysis) tested, 26 and 9 tPRS were 415 associated (p<0.017) with gene expression (Tables S8-S9) in whole blood and considered 416 validated as IVs. 417 418 Evidence of causal association between transcripts and SDB phenotypes 419 We tested the association of the validated tPRS, constructed in a cell-specific manner, with SDB 420 phenotypes in HCHS/SOL (Table S10). Of the 26 tested in BMI unadjusted analysis, 3 tPRS 421 showed evidence of reverse association with SDB phenotypes (p-value<0.05), supporting a 422 causal relationship between expression of these transcripts and SDB traits. Among them, the 423 strongest association was of the tPRS for P2RX4 (Purinergic Receptor P2X 4) in PBMC, in its

424 association with AvgO2, one standard deviation (SD) increase in the PRS was associated with

425 increased 1.9% AvgO2. Additionally, tPRS for *SEC14L2* (SEC14 Like Lipid Binding 2) was

426 negatively associated with AHI in T-cells and tPRS for *TUBB6* (Tubulin Beta 6 Class V) was

427 positively associated with MinO2 in monocytes. After BMI adjustment, only *P2RX4* remained

428 positively associated with AvgO2 in PBMCs (p-value <0.05), as shown in **Table S11**.

429

430 Evidence of causal association between transcripts and metabolites

431	We tested the relation between each validated tPRS and metabolites in HCHS/SOL. The tPRS
432	for P2RX4 and CTD-2366F13.1 (also known as MOCS2-DT, MOCS2 Divergent Transcript)
433	were associated with a total of 6 and 7 metabolites in unadjusted BMI and adjusted BMI
434	analyses (FDR p-value < 0.05, Table S12 and Tables S13), respectively; the association
435	"chains" are visualized in Figure 4. Of 7 metabolites, 3 of them (butyrylcarnitine, linoleoyl-
436	arachidonoyl-glycerol (18:2/20:4), and palmitoleoyl-linoleoyl-glycerol (16:1/18:2)) were also
437	associated with AvgO2 (Table S15). However, the AvgO2-metabolite associations did not
438	remain after BMI adjustment, suggesting that BMI, rather than SDB, may be driving these
439	associations (Table S16). Of the transcripts, P2RX4 had evidence of a complete chain of
440	association with SDB and metabolites (p-value <0.05) in the BMI unadjusted analysis.

Figure 4. Identified association chains between AvgO2, transcripts, and metabolites



Diagram illustrating the "association chain" relationships between AvgO2, tPRS, and metabolites in BMI unadjusted and BMI adjusted analyses. Dark blue color indicates association between tPRS and metabolites in both BMI unadjusted and adjusted analyses; The light blue color indicates the association between tPRS and metabolite only in BMI adjusted analysis.

443

444 **DISCUSSION**

- 445 Here, we conducted a robust analysis of SDB phenotypes and their multi-omics correlates. We
- 446 first identified transcriptome-wide tissue-specific changes in gene expression associated with
- 447 sleep-related oxyhemoglobin saturation traits and AHI in MESA and then used those transcripts
- 448 to develop genetic proxies for gene expression (tPRS). Next, we generalized and validated
- some of the tPRS in WHI. Finally, we utilized the validated tPRS to further study SDB

450 phenotypes and metabolite associations in HCHS/SOL. Our results support SDB-related
451 leukocyte alterations in gene expression and highlight signaling pathways related to

452 inflammation, thrombosis, and neurotransmission.

453

454 SDB traits were associated with differential expression of many transcripts across three blood 455 cell types (Table S4 and S5, 96 genes with FDR p-value<0.1). Of the top transcripts (8 genes 456 with FDR p-value <0.05), AJUBA expression was positively associated with higher AvgO2 and 457 PDGFC expression was negatively associated with higher MinO2 in PBMCs. AJUBA is a 458 scaffold protein in the family of LIM domain-containing protein, considered key regulators of the 459 hypoxic response (47). Recent research supports a role for AJUBA in interacting with retinoic 460 acid receptor signaling in an in vitro model (48) and a role for indirectly limiting inflammation by 461 maintaining mitochondrial quality control in a mouse model (49); therefore, greater AJUBA 462 expression may be associated with increased AvgO2 through pathways related to inflammation 463 and retinoic acid. PDGFC encodes platelet derived growth factor C (50) and is upregulated 464 during hypoxia in tumor cells (51). The association between higher PDGFC expression and 465 lower minimum oxygen saturation (MinO2) supports a role for *PDGFC* signaling in SDB-related 466 hypoxia. In monocytes, EMP1 was linked to MinO2, and prior studies have shown that EMP1 467 expression increases during sleep loss and during hypoxia in cancer tissues (52,53). 468 Correlations between leukocyte subsets and trait-specific gene expression (Figure 3) supported 469 an overall pattern of similarity between cell populations, but also highlighted some striking 470 differences. For example, the gene HPCAL4 (Hippocalcin-Like Protein 4) has high expression 471 changes with "worse" SDB phenotypes (higher AHI, lower AvgO2 and MinO2) in monocytes, but 472 weak associations in T-cells and PBMCs. However, FAM106A and SERPINE2 have lower 473 expression with worse SDB phenotypes in T-cells, but weak associations in PBMCs and 474 monocytes. SERPINE2 (54) encodes glia-derived nexin (GDN, also referred to as protease 475 nexin-1) with mixed evidence as a genetic factor for COPD (55,56). SERPINE2/GDN inhibits the

hypoxia-triggered serine protease thrombin (57,58), and a mouse model of *SERPINE2*deficiency causes excess thrombin activity and overproduction of cytokines in the lungs (59),
suggesting a role for *SERPINE2* in airway inflammation. Since OSA may be associated with a
procoagulant state featuring high thrombin levels (60,61), the hypoxemia associated with OSA
may lead to increased thrombin levels, affecting *SERPINE2* expression in T-cells.

481

482 Of the top differentially expressed genes in MESA whose tPRS was validated in an independent 483 cohort (WHI), only P2RX4 was found to have a complete "chain" of association with SDB and 484 metabolites when tested in another independent study, HCHS/SOL. The PRS for P2RX4 was 485 positively associated with AvgO2, both with and without adjustment for BMI, and as such it is a 486 candidate contributor to oxyhemoglobin saturation in SDB. P2RX4 encodes a purinergic 487 receptor for ATP, P2X₄, which may play a role in the neuroprotective effects of hypoxic 488 preconditioning (62.63). P2RX4 was further negatively associated with metabolite 489 butyrylcarnitine, an indicator of fatty acid metabolism previously linked to BMI (64). Higher 490 oxygen tension promotes increased ATP production (65), which may in turn promote increased 491 P2RX4 expression (P2X₄ as a purinergic ATP receptor) and decreased butyrylcarnitine (66). 492 P2RX4 can have beneficial or detrimental effects depending on context. A mouse model of 493 genetically increased P2XR4 expression led to enhanced cardiovascular function (67) and prior 494 research supports a role for P2XR4 in heart contractility (68), suggesting that P2XR4 may 495 positively drive AvgO2 via bolstering cardiac force. Likewise, butyrylcarnitine was found to be 496 associated with time of cardiac isovolumetric relaxation and may be a marker of heart failure 497 (69), further linking P2XR4 to cardiac function. While CTD-2366F13.1 (MOCS2-DT) was not 498 associated with SDB traits, two of the four metabolites negatively associated with CTD-499 2366F13.1 were also associated with AvgO2: linoleoyl-arachidonoyl- glycerol (18:2/20:4) and 500 palmitoleoyl-linoleoyl-glycerol (16:1/18:2). Levels of 2-Arachidonoylglycerol, an agonist of the 501 CB1 and CB2 cannabinoid receptors, are increased in the brain during ischemia (70) and in

macrophages in response to oxidative stress (71). Therefore, greater AvgO2 levels may result
 in decreased linoleoyl-arachidonoyl- glycerol (18:2/20:4) levels.

504

505 There are several strengths and some limitations of our analysis. Our unique study design 506 exploited a stepwise discovery/validation approach across multiple studies and optimized the 507 availability of SDB-related datasets to study omics markers and SDB. First, we identified SDB-508 related transcripts. Next, we utilized genetic associations with gene expression to construct 509 tPRS, serving as "genetic IVs": exposure variables that are likely associated with the gene 510 transcripts and are specific to them, thus allowing for downstream association analysis and 511 causal inference using these IVs instead of the transcript themselves (72). The idea of using 512 genetic variants as IVs is often used in Mendelian Randomization (MR) analysis. Our analysis is 513 different than standard one-sample MR in that we did not estimate the effect of the transcript on 514 the outcome, because we did not have access to RNA-seg in HCHS/SOL. However, for 515 causality inference, it is sufficient to test the IV association with the outcome of interest (73). We 516 then studied the evidence for the effect of gene expression on SDB using the tPRS. Still, the 517 exact form of association between the gene expression and SDB traits cannot be determined 518 (Figure 2). For example, if no tPRS-SDB association was detected, it is possible that this was 519 due to lack of power. Even in the absence of tPRS-SDB association, the association between 520 the SDB and tPRS can be due to either causal effect of SDB on tPRS, or confounding by a 521 common cause of both. Notably, during the WHI validation step, many transcripts did not have 522 significant tPRS associations and therefore were not carried forward for the genetic association 523 analysis in HCHS/SOL; lack of validation may be due to cell type differences, as we validated 524 tPRS in WHI, where gene expression was measured in whole blood, unlike measurement in 525 specific cell types in MESA. Finally, we leveraged the validated tPRS to test for associations of 526 gene transcript expression with metabolites and connect possible "chains" of associations. All 527 included cohorts are large and represent diverse populations in the U.S. Our sleep cohorts,

528 HCHS/SOL and MESA, have objective sleep phenotype measurement without prior selection of 529 participants based on specific phenotypes. Other limitations of our study include high multiple 530 testing burden, performing procedures with multiple steps, utilizing multiple data in constructing 531 tPRS, and differences in sample timing between blood sample collection and overnight PSG in 532 MESA. However, genetic data should not be affected by differences in timing, and chronic 533 conditions like SDB may be stable over time, making this limitation less of a concern. It is 534 notable that the three blood cell types used in MESA are not distinct: PBMCs include monocytes 535 and T-cells. Further, both monocytes and T-cells are also composed of more granular cell types. 536 Statistical analyses within one cell type are generally powered to detect associations that hold 537 across the component, more granular, cell types, and some cell type-specific associations may 538 be masked. Overall, we utilize robust statistical methods and objective measures, integrating 539 across multiple layers of biological measures, to interrogate the mechanisms driving SDB-540 related morbidity.

541

542 CONCLUSION

543 In summary, we examined multiple levels of biological information to investigate signaling 544 mechanisms underlying SDB traits to better understand drivers of morbidity in SDB. Our results 545 highlight differential gene expression by circulating leukocyte populations in relation to multiple 546 SDB traits related to hypoxia, neurotransmission, and thrombolytic activity. Analyses with 547 validated tPRS in independent cohorts support a mechanistic role for P2XR4 purinergic 548 signaling in SDB, a gene known to influence cardiac function, which is relevant to SDB as both 549 a risk factor and outcome. Overall, we applied novel, robust methods to integrate multi-omic 550 data and SDB data to discover mechanisms underlying multiple SDB traits. Our multi-551 dimensional approach using large population cohorts is a promising approach to unravel 552 biological underpinnings of complex human disorders.

554 **ACKNOWLEDGEMENTS**

555 The authors thank the staff and participants of HCHS/SOL, MESA, and WHI, for their important

- 556 contributions. We gratefully acknowledge the investigators and participants who provided
- 557 biological samples and data for TOPMed.
- 558

559 **FUNDING**

- 560 This work was supported by the National Heart Lung and Blood Institute grants R35HL135818
- to S.R., T32-HL007901 to D.C-T., and R21HL145425 to T.S. Molecular data for the Trans-
- 562 Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung
- and Blood Institute (NHLBI). Genome Sequencing for "NHLBI TOPMed: Multi-Ethnic Study of
- 564 Atherosclerosis (MESA)" (phs001416.v1.p1) was performed at the Broad Institute Genomics
- 565 Platform (HHSN268201500014C). RNA-Seq for "NHLBI TOPMed: Multi-Ethnic Study of
- 566 Atherosclerosis (MESA)" (phs001416.v1.p1) was performed at the Northwest Genomics Center
- 567 (HHSN268201600032I). Genome Sequencing for "NHLBI TOPMed: Women's Health Inititative
- 568 (WHI)" (phs001237.v3.p1) was performed at the Broad Institute Genomics Platform
- 569 (HHSN268201500014C). RNA-Seq for "NHLBI TOPMed: Women's Health Inititative (WHI)"

570 (phs001237.v3.p1) was performed at the Broad Institute Genomics Platform

571 (HHSN268201600034I). Core support including centralized genomic read mapping and

- 572 genotype calling, along with variant quality metrics and filtering were provided by the TOPMed
- 573 Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core
- 574 support including phenotype harmonization, data management, sample-identity QC, and
- 575 general program coordination were provided by the TOPMed Data Coordinating Center
- 576 (R01HL-120393; U01HL-120393; contract HHSN2682018000011). The MESA projects are
- 577 conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in
- 578 collaboration with MESA investigators. Support for the Multi-Ethnic Study of Atherosclerosis
- 579 (MESA) projects are conducted and supported by the National Heart, Lung, and Blood Institute

580 (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 581 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 582 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, 583 N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-584 HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, 585 UL1-TR-001420, UL1TR001881, DK063491, and R01HL105756. The authors thank the other 586 investigators, the staff, and the participants of the MESA study for their valuable 587 contributions. A fill list of participating MESA investigators and institutes can be found at 588 http://www.mesa-nhlbi.org. The WHI program is funded by the National Heart, Lung, and Blood 589 Institute, National Institutes of Health, U.S. Department of Health and Human Services through 590 contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 591 75N92021D00005. The Hispanic Community Health Study/Study of Latinos is a collaborative 592 study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the 593 University of North Carolina (HHSN2682013000011 / N01-HC-65233), University of Miami 594 (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine 595 (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago 596 (HHSN268201300003I / N01- HC-65236 Northwestern Univ), and San Diego State University 597 (HHSN268201300005I / N01-HC-65237). The following Institutes/Centers/Offices have 598 contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on 599 Minority Health and Health Disparities, National Institute on Deafness and Other 600 Communication Disorders, National Institute of Dental and Craniofacial Research, National 601 Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological 602 Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis 603 Center at the University of Washington was supported by NHLBI and NIDCR contracts 604 (HHSN268201300005C AM03 and MOD03). Support for metabolomics data was graciously 605 provided by the JLH Foundation (Houston, Texas).

6	n	6
υ	υ	υ

607

608 AUTHOR CONTRIBUTIONS

- 609 T.S. supervised the research. N.K. and T.S. conceptualized and conducted the biostatistical and
- bioinformatics analyses. N.K., T.S., and D.A.W. interpreted the results and wrote and edited the
- 611 manuscript. Y.Z., B.Y, B.C., H.W., H.M.O-B, A.P.R., A.R.R., J.D.S., J.C., M.D., P.C.Z., R.K.,
- 612 C.K., S.S.R., J.I.R., S.A.G, and S.R. read and approved the final manuscript.

613

- 614 **COI**
- 615 The authors declare that they have no competing interests.

616

617 DATA AVAILABILITY STATEMENT

618 MESA, HCHS/SOL and WHI data are available through application to dbGaP according to the

- 619 study specific accessions. MESA phenotypes are available in: phs000209; WHI phenotypes:
- 620 phs000200; and HCHS/SOL phenotypes: phs000810. HCHS/SOL genotyping data: phs000880.
- 621 MESA and WHI RNA-seq data has been deposited and will become available through the TOP-
- Med according to the study specific accessions; MESA: phs001416 ; WHI: phs000972.
- 623 HCHS/SOL metabolomics data are available via data use agreement with the HCHS/SOL Data
- 624 Coordinating Center at the University of North Carolina at Chapel Hill, see collaborators web-
- 625 site: <u>https://sites.cscc.unc.edu/hchs/</u>. Data needed to construct the tPRS are publicly available
- 626 on the repository https://github.com/nkurniansyah/SDB_Multi_Omics.

628 Bibliography

- 630 1. Rundo JV. Obstructive sleep apnea basics. Cleve Clin J Med. 2019 Sep;86(9 Suppl 1):2–9.
- 631 2. Mehra R, Stone KL, Blackwell T, Ancoli Israel S, Dam T-TL, Stefanick ML, et al.
- 632 Prevalence and correlates of sleep-disordered breathing in older men: osteoporotic
 633 fractures in men sleep study. J Am Geriatr Soc. 2007 Sep;55(9):1356–64.
- Redline S, Kump K, Tishler PV, Browner I, Ferrette V. Gender differences in sleep
 disordered breathing in a community-based sample. Am J Respir Crit Care Med. 1994
 Mar;149(3 Pt 1):722–6.
- 637 4. Osorio RS, Gumb T, Pirraglia E, Varga AW, Lu S-E, Lim J, et al. Sleep-disordered
 638 breathing advances cognitive decline in the elderly. Neurology. 2015 May 12;84(19):1964–
 639 71.
- 640 5. Botros N, Concato J, Mohsenin V, Selim B, Doctor K, Yaggi HK. Obstructive sleep apnea
 641 as a risk factor for type 2 diabetes. Am J Med. 2009 Dec;122(12):1122–7.
- 642 6. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between
 643 sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378–
 644 84.
- Li X, Sotres-Alvarez D, Gallo LC, Ramos AR, Aviles-Santa L, Perreira KM, et al.
 Associations of Sleep-disordered Breathing and Insomnia with Incident Hypertension and
 Diabetes. The Hispanic Community Health Study/Study of Latinos. Am J Respir Crit Care
 Med. 2021 Feb 1;203(3):356–65.
- 649 8. Chami HA, Fontes JD, Vasan RS, Keaney JF, O'Connor GT, Larson MG, et al. Vascular
 650 inflammation and sleep disordered breathing in a community-based cohort. Sleep. 2013
 651 May 1;36(5):763–768C.
- 9. Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. Rev Endocr
 Metab Disord. 2015 Mar;16(1):25–34.
- de Paula LKG, Alvim RO, Pedrosa RP, Horimoto ARVR, Krieger JE, Oliveira CM, et al.
 Heritability of OSA in a rural population. Chest. 2016 Jan 6;149(1):92–7.
- Carmelli D, Colrain IM, Swan GE, Bliwise DL. Genetic and environmental influences in
 sleep-disordered breathing in older male twins. Sleep. 2004 Aug 1;27(5):917–22.
- Ryan S, Cummins EP, Farre R, Gileles-Hillel A, Jun JC, Oster H, et al. Understanding the
 pathophysiological mechanisms of cardiometabolic complications in obstructive sleep
 apnoea: towards personalised treatment approaches. Eur Respir J. 2020 Aug 6;56(2).
- Baguet J-P, Hammer L, Lévy P, Pierre H, Launois S, Mallion J-M, et al. The severity of
 oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest.
 2005 Nov;128(5):3407–12.
- 14. Nácher M, Serrano-Mollar A, Farré R, Panés J, Seguí J, Montserrat JM. Recurrent
 obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea.
 Respir Physiol Neurobiol. 2007 Jan 15;155(1):93–6.
- 15. Dematteis M, Godin-Ribuot D, Arnaud C, Ribuot C, Stanke-Labesque F, Pépin J-L, et al.
 Cardiovascular consequences of sleep-disordered breathing: contribution of animal models
 to understanding the human disease. ILAR J. 2009;50(3):262–81.
- 670 16. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood
 671 gammadelta T cells in sleep apnea. Am J Respir Crit Care Med. 2003 Jul 15;168(2):242–9.
- Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and
 production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir

- 674 Crit Care Med. 2002 Apr 1;165(7):934–9.
- Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, et al.
 Elevated production of tumor necrosis factor-alpha by monocytes in patients with
 obstructive sleep apnea syndrome. Chest. 2004 Nov;126(5):1473–9.
- Bergeron C, Kimoff J, Hamid Q. Obstructive sleep apnea syndrome and inflammation. J
 Allergy Clin Immunol. 2005 Dec;116(6):1393–6.
- 680 20. Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR. Treatment of obstructive sleep
 681 apnea alters cancer-associated transcriptional signatures in circulating leukocytes. Sleep.
 682 2014 Apr 1;37(4):709–14, 714A.
- Perry JC, Guindalini C, Bittencourt L, Garbuio S, Mazzotti DR, Tufik S. Whole blood
 hypoxia-related gene expression reveals novel pathways to obstructive sleep apnea in
 humans. Respir Physiol Neurobiol. 2013 Dec 1;189(3):649–54.
- Turnbull CD, Lee LYW, Starkey T, Sen D, Stradling J, Petousi N. Transcriptomics
 Identify a Unique Intermittent Hypoxia-mediated Profile in Obstructive Sleep Apnea. Am J
 Respir Crit Care Med. 2020 Jan 15;201(2):247–50.
- Sofer T, Li R, Joehanes R, Lin H, Gower AC, Wang H, et al. Transcriptional survey of
 peripheral blood links lower oxygen saturation during sleep with reduced expressions of
 CD1D and RAB20 that is reversed by CPAP therapy. medRxiv. 2019 Aug 12;
- 692 24. Polotsky VY, Bevans-Fonti S, Grigoryev DN, Punjabi NM. Intermittent hypoxia alters
 693 gene expression in peripheral blood mononuclear cells of healthy volunteers. PLoS One.
 694 2015 Dec 14;10(12):e0144725.
- Alterki A, Joseph S, Thanaraj TA, Al-Khairi I, Cherian P, Channanath A, et al. Targeted
 Metabolomics Analysis on Obstructive Sleep Apnea Patients after Multilevel Sleep
 Surgery. Metabolites. 2020 Sep 1;10(9).
- Ku H, Zheng X, Jia W, Yin S. Chromatography/Mass Spectrometry-Based Biomarkers in
 the Field of Obstructive Sleep Apnea. Medicine. 2015 Oct;94(40):e1541.
- 27. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi27. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi2002 Nov
 2002 Nov
 2002 1;156(9):871-81.
- 28. Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcántara C, et al. Racial/Ethnic
 Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA).
 Sleep. 2015 Jun 1;38(6):877–88.
- Pays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003 Oct;13(9
 Suppl):S18-77.
- 30. Sorlie PD, Avilés-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello
 AL, et al. Design and implementation of the Hispanic Community Health Study/Study of
 Latinos. Ann Epidemiol. 2010 Aug;20(8):629–41.
- 31. Lavange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, et al.
 Sample design and cohort selection in the Hispanic Community Health Study/Study of
 Latinos. Ann Epidemiol. 2010 Aug;20(8):642–9.
- Conomos MP, Laurie CA, Stilp AM, Gogarten SM, McHugh CP, Nelson SC, et al. Genetic diversity and association studies in US hispanic/latino populations: applications in the hispanic community health study/study of latinos. Am J Hum Genet. 2016 Jan 7:98(1):165–84.
- 719 33. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, et al. Use of >100,000

- NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome
 sequences improves imputation quality and detection of rare variant associations in
 admixed African and Hispanic/Latino populations. PLoS Genet. 2019 Dec
 23;15(12):e1008500.
- Feofanova EV, Chen H, Dai Y, Jia P, Grove ML, Morrison AC, et al. A Genome-wide
 Association Study Discovers 46 Loci of the Human Metabolome in the Hispanic
- Community Health Study/Study of Latinos. Am J Hum Genet. 2020 Nov 5;107(5):849–63.
 Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or
 without a reference genome. BMC Bioinformatics. 2011 Aug 4;12:323.
- 36. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted
 ultrahigh performance liquid chromatography/electrospray ionization tandem mass
 spectrometry platform for the identification and relative quantification of the smallmolecule complement of biological systems. Anal Chem. 2009 Aug 15:81(16):6656–67.
- 37. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. Untargeted
 metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer
 344 male rats. Toxicol Pathol. 2009 Jun;37(4):521–35.
- 38. Sofer T, Kurniansyah N, Aguet F, Ardlie K, Durda P, Nickerson DA, et al. Benchmarking
 association analyses of continuous exposures with RNA-seq in observational studies. Brief
 Bioinformatics. 2021 May 20;
- 39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B
 (Methodological). 1995 Jan;57(1):289–300.
- 40. Sofer T, Zheng X, Gogarten SM, Laurie CA, Grinde K, Shaffer JR, et al. A fully adjusted
 two-stage procedure for rank-normalization in genetic association studies. Genet
 Epidemiol. 2019 Jan 17;43(3):263–75.
- 745 41. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
 746 Gigascience. 2019 Jul 1;8(7).
- 42. Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, et al. Genetic association
 testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019 Dec
 15;35(24):5346–8.
- 43. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al.
 A gene-based association method for mapping traits using reference transcriptome data.
 Nat Genet. 2015 Sep;47(9):1091–8.
- 44. Mogil LS, Andaleon A, Badalamenti A, Dickinson SP, Guo X, Rotter JI, et al. Genetic
 architecture of gene expression traits across diverse populations. PLoS Genet. 2018 Aug
 10;14(8):e1007586.
- 756 45. Lumley T. Package "survey." R package version. 2015;
- 757 46. Lumley T. Complex surveys: a guide to analysis using R. 2011;
- 47. Bridge KS, Sharp TV. Regulators of the hypoxic response: a growing family. Future
 Oncol. 2012 May;8(5):491–3.
- 48. Hou Z, Peng H, White DE, Negorev DG, Maul GG, Feng Y, et al. LIM protein Ajuba
 functions as a nuclear receptor corepressor and negatively regulates retinoic acid signaling.
 Proc Natl Acad Sci USA. 2010 Feb 16;107(7):2938–43.
- 763 49. Ponia SS, Robertson SJ, McNally KL, Subramanian G, Sturdevant GL, Lewis M, et al.
- Mitophagy antagonism by ZIKV reveals Ajuba as a regulator of PINK1 signaling, PKR dependent inflammation, and viral invasion of tissues. Cell Rep. 2021 Oct

- 766 26;37(4):109888.
- 767 50. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C
 768 and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J.
 769 2005 Nov;272(22):5723-41.
- Clara CA, Marie SKN, de Almeida JRW, Wakamatsu A, Oba-Shinjo SM, Uno M, et al.
 Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in human
 glioblastoma. Neuropathology. 2014 Aug;34(4):343–52.
- Arnardottir ES, Nikonova EV, Shockley KR, Podtelezhnikov AA, Anafi RC, Tanis KQ, et
 al. Blood-gene expression reveals reduced circadian rhythmicity in individuals resistant to
 sleep deprivation. Sleep. 2014 Oct 1;37(10):1589–600.
- 53. Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, et al. Intermittent
 hypoxia induces a metastatic phenotype in breast cancer. Oncogene. 2018
 Aug;37(31):4214–25.
- 54. Monard D. SERPINE2/Protease Nexin-1 in vivo multiple functions: Does the puzzle make
 sense? Semin Cell Dev Biol. 2017 Feb;62:160–9.
- 55. Demeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedon JC, et al. The
 SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum
 Genet. 2006 Feb;78(2):253–64.
- 56. Chappell S, Daly L, Morgan K, Baranes TG. The SERPINE2 gene and chronic obstructive
 pulmonary disease. American journal of. 2006;
- 57. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell.
 1980 Aug;21(1):37–45.
- 58. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, et
 al. Thrombin Activates the Hypoxia-Inducible Factor-1 Signaling Pathway in Vascular
 Smooth Muscle Cells. Circ Res. 2001 Jul 6;89(1):47–54.
- 59. Solleti SK, Srisuma S, Bhattacharya S, Rangel-Moreno J, Bijli KM, Randall TD, et al.
 Serpine2 deficiency results in lung lymphocyte accumulation and bronchus-associated
 lymphoid tissue formation. FASEB J. 2016 Jul;30(7):2615–26.
- 795 60. Zolotoff C, Bertoletti L, Gozal D, Mismetti V, Flandrin P, Roche F, et al. Obstructive
 796 Sleep Apnea, Hypercoagulability, and the Blood-Brain Barrier. J Clin Med. 2021 Jul
 797 14;10(14).
- 61. Liak C, Fitzpatrick M. Coagulability in obstructive sleep apnea. Can Respir J. 2011
 Dec;18(6):338–48.
- 62. Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund PE, Stühmer W. Characterization
 of recombinant human P2X4 receptor reveals pharmacological differences to the rat
 homologue. Mol Pharmacol. 1997 Jan;51(1):109–18.
- 63. Ozaki T, Muramatsu R, Sasai M, Yamamoto M, Kubota Y, Fujinaka T, et al. The P2X4
 receptor is required for neuroprotection via ischemic preconditioning. Sci Rep. 2016 May
 13;6:25893.
- Moore SC, Matthews CE, Sampson JN, Stolzenberg-Solomon RZ, Zheng W, Cai Q, et al.
 Human metabolic correlates of body mass index. Metabolomics. 2014 Apr 1;10(2):259–69.
- 808 65. Bardsley EN, Pen DK, McBryde FD, Ford AP, Paton JFR. The inevitability of ATP as a
 809 transmitter in the carotid body. Auton Neurosci. 2021 Sep;234:102815.
- 810 66. Zolkipli-Cunningham Z, Naviaux JC, Nakayama T, Hirsch CM, Monk JM, Li K, et al.
 811 Metabolic and behavioral features of acute hyperpurinergia and the maternal immune

812 813		activation mouse model of autism spectrum disorder. PLoS One. 2021 Mar 18:16(3):e0248771
814 815	67.	Yang A, Sonin D, Jones L, Barry WH, Liang BT. A beneficial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of
816 817	68.	cardiomyopathy. Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1096-103. Hu B, Mei QB, Yao XJ, Smith E, Barry WH, Liang BT. A novel contractile phenotype
818 819		with cardiac transgenic expression of the human P2X4 receptor. FASEB J. 2001 Dec:15(14):2739–41.
820 821	69.	Razavi AC, Bazzano LA, He J, Fernandez C, Whelton SP, Krousel-Wood M, et al. Novel findings from a metabolomics study of left ventricular diastolic function: the bogalusa
822 823 824	70.	heart study. J Am Heart Assoc. 2020 Feb 4;9(3):e015118. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis. 2006
825 826 827	71.	Oct;24(1):15–27. Matthews AT, Lee JH, Borazjani A, Mangum LC, Hou X, Ross MK. Oxyradical stress increases the biosynthesis of 2-arachidonoylglycerol: involvement of NADPH oxidase. Am
828 829 830	72.	von Hinke S, Davey Smith G, Lawlor DA, Propper C, Windmeijer F. Genetic markers as instrumental variables. J Health Econ. 2016 Jan;45:131–48.
831 832	73.	VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology. 2014 May;25(3):427–35.
833 834		
835		
836		
837		
838		
839		
840		
841		
842		
843		
844		
845		
846		
84/		

848 849	An integrated multi-omics analysis of sleep-disordered breathing traits across mul- tiple blood cell types
850 851	Kurniansyah et al.
852 853	Supplemental Methods
854	The Multi-Ethnic Study of Atherosclerosis (MESA)35
855	The Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
856	Genotyping and imputation in HCHS/SOL37
857	The Women's Health Initiative (WHI)37
858	RNA sequencing in WHI38
859	Supplemental figures
860 861	Figure S1: MESA data flow across various measures in the 1 st and 5 th exam, and the sleep ancillary study
862	Figure S2: HCHS/SOL data flow across genotyping, metabolomics, and sleep data40
863 864	Figure S3: Heatmap of estimated log-fold gene expression change with SDB phenotypes across tissues without BMI adjustment in MESA41
865 866	Figure S4: Heatmap of estimated log-fold gene expression change with SDB phenotypes across tissues from BMI-adjusted analysis in MESA42
867 868	Figure S5: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in BMI adjusted analysis in MESA (top genes)43
869	Table S6. Correlation between the SDB phenotypes44
870 871	Figure S7: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in analysis without BMI adjustment (all genes)45
872 873	Figure S8: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in analysis BMI adjustment (all genes)
874 875	Figure S9. Comparison of the associations between monocyte-based tPRSs and whole-blood gene expression in WHI47
876 877 878	References
879 880	Supplemental Methods
881 882	The Multi-Ethnic Study of Atherosclerosis (MESA)

883 MESA is a longitudinal cohort study (27), established in 2000, that prospectively collected risk 884 factors for development of subclinical and clinical cardiovascular disease among participants in 885 six field centers across the United States (Baltimore City and Baltimore County, MD; Chicago, 886 IL; Forsyth County, NC; Los Angeles County, CA; Northern Manhattan and the Bronx, NY; and 887 St. Paul. MN). The 1st and 5th MESA exams took place between 2000-2002, and 2010-2012. 888 respectively, and whole blood was drawn from participants in both exams. For about 1,400 889 participants, blood was used later for RNA extraction and/or proteomics in at least one of the 890 exams. In addition, a sleep study ancillary to MESA occurred shortly after MESA exam 5 during 891 2010-2013. Sleep study participants underwent single night in-home polysomnography 892 (Computedics Somte Systems, Abbotsville, Australia, AU), as previously described (28). The 893 number of individuals with each type of data and at each time point (exam 1 and exam 5) varies. 894 Figure S1 in the Supplementary Information visualizes the data flow and overlaps across the 895 various measures used in this study: whole-genome genotyping, RNA-seg, and sleep. The 896 study was approved by Institutional Review Boards in all study centers and participants 897 provided written informed consent. 898

899 The Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

900

901 The HCHS/SOL is a longitudinal cohort study of U.S. Hispanics/Latinos (30,31) recruited from 902 four geographic regions: Bronx NY, Chicago IL, Miami FL, and San Diego CA. The HCHS/SOL 903 baseline exam occurred on 2008-2011, where 16,415 participants were enrolled via multi-stage 904 probability sampling. HCHS/SOL individuals who consented further participated in an in-home 905 sleep study, using a validated type 3 home sleep apnea test recording airflow (via nasal 906 pressure), oximetry, position, and snoring (ARES Unicorder 5.2; B-Alert). Genetic data were 907 measured and imputed to the TOPMed freeze 5b reference panel as previously described, for 908 individuals who consented at baseline (32,33). More information about genotyping and

909 imputation is provided in the Supplementary Information. Metabolomic data were also measured 910 for n=~4,000 individuals selected at random out of those with genetic data (34). Figure S2 in 911 the Supplementary Information provides the data flow in HCHS/SOL, focusing on individuals 912 with genetic data and wide consent for genetic data sharing. All participants provided written 913 informed consent at their recruitment site and the study was approved by the institutional review 914 boards at all participating institutions.

- 915 Genotyping and imputation in HCHS/SOL
- 916

917 Blood was drawn from HCHS/SOL participants during the baseline exam. Individuals who con-

918 sented to genetic studies were genotyped using an Illumina Omni2.5M array, which included

919 150,000 custom-selected Single Nucleotide Polymorphisms (SNPs) including ancestry-informa-

920 tive and Amerindian-specific variants. Global ancestry proportions measuring the proportion of

921 the genome inherited from European, African, and Amerindian ancestors and genetic principal

922 components were computed as previously reported [1]. The genotypes were imputed to the

923 Trans-Omics in Precision Medicine (TOPMed) freeze 5b reference panel as described in [2].

924

926

925 The Women's Health Initiative (WHI)

927 The WHI is a prospective national health study focused on identifying optimal strategies for pre-928 venting chronic diseases that are the major causes of death and disability in postmenopausal 929 women [3]. The WHI initially recruited 161,808 women between 1993 and 1997 with the goal of 930 including a socio-demographically diverse population with racial/ethnic minority groups propor-931 tionate to the total minority population of US women aged 50-79 years. The WHI consists of two 932 major parts: a set of randomized Clinical Trials and an Observational Study. The WHI Clinical 933 Trials (CT; N=68,132) includes three overlapping components, each a randomized controlled 934 comparison: the Hormone Therapy Trials (HT), Dietary Modification Trial, and Calcium and Vita-935 min D Trial. A parallel prospective observational study (OS; N = 93,676) examined biomarkers

936	and risk factors associated with various chronic diseases. While the HT trials ended in the mid-
937	2000s, active follow up of the WHI-CT and WHI-OS cohorts has continued for over 25 years
938	with the accumulation of large numbers of diverse clinical outcomes, risk factor measurements,
939	medication use, and many other types of data.
940	A total of 11,071 WHI participants have whole-genome sequencing data via TOPMed, and
941	1,274 of these participants have RNA-seq measured in venous blood via TOPMed.
942 943 944 945	RNA sequencing in WHI RNA-seq was performed via the Trans-Omics in Precision Medicine (TOPMed) program. The
946	WHI RNA samples (N=1,335) were collected from Long Life Study (LLS) participants as part of
947	the LLS Blood Protocol using the PreAnalytiX PAXgene blood tubes, a collection system de-
948	signed to preserve RNA from whole blood. After collection in participant's homes throughout the
949	US, PAXgene tubes were the last of five tubes drawn from each participant, mixed carefully (in-
950	verted 8-10 times), kept at room temperature for a minimum of 2 hours post draw, and shipped
951	overnight with cool packs to the Fred Hutch Specimen Processing Lab (SPL). Upon receipt at
952	the SPL, PAXgene tubes were stored at -80 degrees C until they could be transferred to the
953	Fred Hutch Public Health Sciences Biomarker Lab, where the vials were kept frozen at -80 de-
954	grees C. Within about a month of collection, the lab extracted total RNA, including miRNA, using
955	the PreAnalytiX method (PAXgene Blood miRNA Kit Handbook, Qiagen, 05/2009) designed for
956	use with the PAXgene blood collection tubes. A qualitative assessment by agarose gel electro-
957	phoresis of RNA integrity was done at the time of extraction. The RNA was quantified by
958	NanoDrop. The elution volume of 76 μL of extracted RNA was divided between two RNA 'Par-
959	ent' vials without further dilution, frozen at -80 degrees C, and shipped overnight on dry ice to
960	the WHI biorepository for long-term storage at -80 degrees C. RNA sequencing for WHI was
961	performed at the Broad Institute using the unified TOPMed protocols. More information about

- 962 RNA sequencing protocols in TOPMed is available here <u>https://github.com/broadinstitute/gtex-</u>
- 963 pipeline/blob/master/TOPMed_RNAseq_pipeline.md.
- 964
- 965

966 Supplemental figures

967

Figure S1: MESA data flow across various measures in the 1st and 5th exam, and the sleep ancillary study.



The figure focuses on n=5,468 individuals having at least one of the displayed measures.



Figure S2: HCHS/SOL data flow across genotyping, metabolomics, and sleep data. Participation in HCHS/SOL datasets







Genes displayed in this figure are those that had FDR p-value<0.1 in association analysis without BMI adjustment. FDR adjustment was computed separately in each set of associations defined by cell type and SDB phenotype. Red color indicated



Figure S4: Heatmap of estimated log-fold gene expression change with SDB phenotypes across tissues from BMI-adjusted analysis in MESA

Genes displayed in this figure are those that had FDR p-value<0.1 in association analysis with BMI adjustment. FDR adjustment was computed separately in each set of associations defined by cell type and SDB phenotype.



Figure S5: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in BMI adjusted analysis in MESA (top genes)

Heatmap illustrating the Spearman correlations of log-fold change of transcript expression by tissue type (monocytes, T-cells, PBMCs) and SDB phenotype (AvgO2, MinO2, AHI) in MESA. Correlations were computed over genes with FDR p<0.1. Color legend portrays Spearman R^2 (no/weak correlation = light yellow; complete/strong correlation = green). Estimated AHI effect sizes are flipped prior to computation of correlations so that they match the direction of MinO2 and AvgO2.

- 999
- 1000
- 1001



Heatmap illustrating the Spearman correlations SDB phenotype (AvgO2, MinO2, AHI). Color legend portrays Spearman R^2 (no/weak correlation = light yellow; complete/strong correlation = green).





Figure S7: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in analysis without BMI adjustment (all genes).

Heatmap illustrating the Spearman correlations of log-fold change of transcript expression by tissue type (monocytes, T-cells, PBMCs) and SDB phenotype (AvgO2, MinO2, AHI). Color legend portrays Spearman R² (no/weak correlation = light yellow; complete/strong correlation = green).

1003

1004 1005

1005

1000



Figure S8: Spearman correlations between estimated log-fold changes in gene expression across SDB phenotypes and tissues in analysis BMI adjustment (all genes).

Heatmap illustrating the Spearman correlations of log-fold change of transcript expression by tissue type (monocytes, T-cells, PBMCs) and SDB phenotype (AvgO2, MinO2, AHI). Color legend portrays Spearman R^2 (no/weak correlation = light yellow; complete/strong correlation = green).

Figure S9. Comparison of the associations between monocyte-based tPRSs and whole-blood gene expression in WHI



◆ tPRS1 ◆ tPRS2 ◆ tPRS3

For each transcript associated with an SDB phenotype, the figure provides the estimated association effect, 95% confidence interval, and p-value, of tPRSs constructed in different approaches with whole-blood transcript expression in WHI. tPRS1 and tPRS3 were constructed using the clump and threshold approach implemented in PRSice2 using summary statistics from GWAS of transcript expression in monocytes in MESA, and with clumping guided by LD in MESA (the same individuals used for GWAS). tPRS1 allows for genome-wide SNPs, and tPRS3 focused on cis-eQTLs. tPRS2 is the prediXcan model (also using cis-eQLTs only). For tPRS1 and 3 we considered three p-value threshold ($5x10^{-8}$, 10^{-7} , and 10^{-6}), and the tPRS with smallest p-value is displayed. PRS associations were estimated in models adjusted for sex, age, study site, race/ethnic background, batch effects, and 11 ancestral principal components.

1018 1019

1020 References

- Conomos, M.P. *et al.* (2016) Genetic diversity and association studies in US hispanic/latino
 populations: applications in the hispanic community health study/study of latinos. *Am. J. Hum. Genet.* 98, 165–184
- 1025 2 Kowalski, M.H. *et al.* (2019) Use of >100,000 NHLBI Trans-Omics for Precision Medicine
- 1026 (TOPMed) Consortium whole genome sequences improves imputation quality and detection
 1027 of rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet.* 1028 15, e1008500
- 1029 3 Hays, J. *et al.* (2003) The Women's Health Initiative recruitment methods and results. *Ann*
- 1030 *Epidemiol* 13, S18-77
- 1031